Why do drug names end in "-mab", "-nib", and "-clax"?

🌏 Available in: English | 한국어

Decoding Drug Names: Why “-mab,” “-nib” and “-clax” Aren’t Random

Generic drug names may look complicated, but many contain clues about how the medicine works.

---

⏱ In 30 Seconds

• ✓ Generic drug names are created through internationally coordinated systems rather than chosen purely for marketing.
• ✓ Shared word fragments called stems can indicate a drug’s pharmacological family or mechanism.
• ✓ Names ending in -nib usually identify kinase inhibitors, while -toclax identifies BCL-2-family inhibitors.
• ✓ Older antibody medicines commonly end in -mab, although the WHO has introduced a new naming system for newly named antibodies.
• ✓ A stem provides a useful clue, but it does not reveal the complete target, indication, safety profile or route of administration.

A Personal Note

This article started with a question I asked myself: why do so many drug names seem to end in the same way? I knew names such as -mab, -nib and -clax were not random, but I wanted to understand what they actually meant. Once I looked into the naming system, I realised it was something worth knowing—and worth sharing.

---

Drug names such as venetoclax, pembrolizumab, imatinib and olaparib can be difficult enough to pronounce, let alone remember.

But once you know what some of their endings mean, the names begin to make a little more sense.

Generic drug names are created through internationally coordinated naming systems intended to make each medicine identifiable, distinct and scientifically informative.

The World Health Organization manages the International Nonproprietary Names, or INN, programme, while the United States Adopted Names Council assigns nonproprietary names in the United States.

These are generic names such as venetoclax and pembrolizumab, not commercial brand names such as Venclexta or Keytruda.

One of the most useful features of this system is the use of stems.

A stem is a shared syllable or word fragment associated with a pharmacological family, chemical class or mechanism of action.

Once you recognise a few common stems, an unfamiliar drug name can begin to reveal part of its scientific identity.

How Generic Drug Names Are Constructed

A nonproprietary drug name commonly contains two broad components:

• A distinctive prefix that helps separate the drug from other members of its class
• A recognised stem or substem that places it within a pharmacological family

The prefix often has no specific scientific meaning.

Its main purpose is to make the name unique and distinguishable from existing medicines.

The stem carries the more useful clue.

For example, recognising the stem in imatinib suggests that the medicine belongs to the kinase-inhibitor family, while the ending of olaparib identifies it as a PARP inhibitor.

However, drug names should not be treated as complete molecular descriptions.

A stem may identify a broad class without revealing the drug’s exact target, approved disease, dosage, safety profile or clinical effectiveness.

-mab: The Classic Monoclonal Antibody Ending

Many familiar biological medicines end in -mab.

Examples include:

• Pembrolizumab
• Trastuzumab
• Rituximab
• Adalimumab

These medicines are monoclonal antibodies: large, laboratory-produced proteins designed to bind selected molecular targets.

One example of how antibody medicines moved from immune biology to therapeutic development is the story of how scientists learned to block GM-CSF.

Some attach to proteins on cancer cells.

Others block inflammatory cytokines, immune checkpoints or cell-surface receptors.

Antibody medicines have become important in cancer, autoimmune disease, infectious disease and many other areas of medicine.

What Did -zumab, -ximab and -umab Mean?

Under the older antibody naming system, syllables before -mab could indicate how much of the antibody sequence was derived from human or non-human sources.

• -ximab was associated with chimeric antibodies
• -zumab was associated with humanised antibodies
• -umab was associated with fully human antibodies

That historical pattern can still help explain the names of established medicines such as rituximab, trastuzumab and adalimumab.

However, it should not be treated as the current system for naming newly developed antibodies.

The New Antibody Naming System

As antibody technologies became more complex, the -mab family became increasingly crowded.

The WHO therefore replaced it for newly assigned antibody names with four new stems:

• -tug — monospecific, full-length immunoglobulins with unmodified constant regions
• -bart — monospecific, full-length immunoglobulins with engineered constant regions
• -mig — bispecific or multispecific immunoglobulins
• -ment — monospecific immunoglobulin fragments and related constructs

Older medicines ending in -mab keep their established names.

The change affects the naming of newer substances rather than renaming medicines already in clinical use.

-nib: Kinase Inhibitors

The ending -nib is associated with kinase inhibitors.

Kinases are enzymes that transfer phosphate groups to other molecules, helping regulate cell growth, survival, metabolism and communication.

Abnormally active kinases can drive cancer by continually telling cells to grow or divide.

Kinase inhibitors are small molecules designed to interrupt those signals.

Examples include:

• Imatinib
• Erlotinib
• Osimertinib
• Acalabrutinib

Imatinib became one of the most influential early examples of targeted cancer therapy.

It inhibits the abnormal BCR–ABL kinase that drives chronic myeloid leukaemia, demonstrating that a cancer could be treated by targeting a specific molecular abnormality.

Many kinase inhibitors are available as tablets or capsules, but the stem itself identifies the pharmacological family rather than guaranteeing a particular dosing schedule or clinical use.

-ciclib: Cyclin-Dependent Kinase Inhibitors

The more specific stem -ciclib identifies inhibitors of cyclin-dependent kinases, commonly called CDKs.

CDKs help control progression through the cell cycle.

Cancer cells can exploit these enzymes to continue dividing.

Examples include:

• Palbociclib
• Ribociclib
• Abemaciclib

These medicines inhibit selected CDKs and are widely recognised for their use in certain forms of hormone receptor-positive breast cancer.

-parib: PARP Inhibitors

Medicines ending in -parib inhibit poly(ADP-ribose) polymerase, usually abbreviated as PARP.

PARP enzymes participate in the repair of damaged DNA.

Some cancer cells already have weaknesses in other DNA-repair systems and become unusually dependent on PARP for survival.

Blocking PARP can therefore create a level of DNA damage that the cancer cell can no longer tolerate.

Examples include:

• Olaparib
• Niraparib
• Rucaparib
• Talazoparib

The success of PARP inhibitors became an important clinical example of synthetic lethality: targeting one repair pathway becomes especially damaging when another pathway is already defective.

-toclax: BCL-2-Family Inhibitors

Venetoclax is often informally recognised by its visible -clax ending.

The formal stem is more precisely -toclax, which identifies inhibitors of proteins within the BCL-2 family.

These proteins regulate apoptosis, the controlled process through which damaged or unnecessary cells destroy themselves.

Some blood cancers become dependent on BCL-2-family survival proteins to prevent apoptosis.

Venetoclax binds selectively to BCL-2, removing a survival signal and allowing the cancer cell’s own death machinery to reactivate.

The long scientific path from BCL-2 biology to a medicine is described in the Australian discovery story behind Venetoclax.

Other names in this broader family include:

• Navitoclax
• Obatoclax
• Venetoclax

The name therefore contains a clue to the biological strategy behind the drug: disabling a protein that protects the cancer cell from programmed death.

Other Drug Stems Worth Recognising

Stem	Drug family	Example
-nib	Kinase inhibitor	Imatinib
-ciclib	Cyclin-dependent kinase inhibitor	Palbociclib
-parib	PARP inhibitor	Olaparib
-toclax	BCL-2-family inhibitor	Venetoclax
-statin	HMG-CoA reductase inhibitor	Atorvastatin
-sartan	Angiotensin receptor blocker	Losartan
-olol	Beta-adrenoceptor blocker	Metoprolol
-prazole	Proton-pump inhibitor	Omeprazole

What a Drug Name Cannot Tell You

Recognising a stem is useful, but it has limits.

A drug name does not necessarily tell you:

• The exact molecular target
• The diseases for which the medicine is approved
• Whether it is more effective than another member of the same class
• Its side effects or drug interactions
• Whether it is given orally, by injection or by infusion
• Whether it is suitable for an individual patient

Two medicines sharing a stem may target different proteins or be approved for different diseases.

The name is therefore a starting clue, not a substitute for prescribing information or clinical evidence.

Why Drug Stems Are Useful

Learning a few common drug stems does not tell you everything about a medicine, but it can give you a useful first clue. A name ending in -nib suggests a kinase inhibitor, -parib points to a PARP inhibitor, and -toclax points to the BCL-2 family.

The system also changes as medicines change. The replacement of -mab with several new antibody stems is a good example of how drug naming continues to evolve alongside biomedical science.

So the next time you encounter an unfamiliar drug name, it may be worth looking at the ending first. It might tell you more than you expect.

Continue Reading

• Venetoclax: The BCL-2 Inhibitor Changing Blood Cancer Treatment
• How Was Venetoclax Developed? The Australian Story Behind a Breakthrough Cancer Therapy
• From Life-Saving Discovery to Drug Target: The Story of GM-CSF
• What Is the Difference Between the Lasker Award and the Nobel Prize?

---

This article provides a general educational introduction to drug-name stems. Naming systems evolve, and a medicine’s name should not be used as a substitute for official prescribing information or professional medical advice.